News

GSK falls as blood cancer drug likely headed for US rejection
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...
STAT2d
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
GSK falls Friday, underperforms market
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
US FDA approves pre-filled version of GSK's shingles vaccine
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...
Global Stocks Recap: Alibaba, Saab, Burberry, GSK
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
Fierce Pharma3d
FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns
On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...
GSK slides Tuesday, underperforms market
GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.
Fierce Biotech5d
GSK telegraphs 'very limited number' of job cuts amid R&D investment spree
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...